Teva Agilect "approvable" again
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva Parkinson's disease treatment Agilect (rasagiline) receives a second "approvable" letter Aug. 4. "There remain a number of issues that Teva believed it had resolved with its submissions, but [where] FDA continues to have concerns," the sponsor states Aug. 5. The firm plans to meet with the agency "promptly" to address the remaining concerns. Teva responded to a July 2004 approvable letter last November, but the review was extended by three months due to a technical error with the NDA...